Iovance Biotherapeutics is trading at $13.02 with a -12.09% pre-market move on October 29; the broader market is weaker, but no clear catalyst is confirmed.
- Updated Phase 2 lung-cancer results showed a 24.6% response rate across 69 patients, consistent with the earlier result; a biomarker-defined subgroup had a 59.1% response rate.
- The company said a supplemental application is planned for 2027. Available reporting does not establish that the results caused the decline.